Table 4.

The efficacy of durvalumab and tremelimumab

Clinical trial information	Subgroup	Evaluable patient (N)	PR ORR % (N) (95% CI)
NCT02536794	Breast cancer	18	3 17
NCT02519348	HCC	40	NM 15
NCT01975831	Cervical cancer Colorectal cancer NTNBC Ovarian cancer RCC	13 11 10 25 11	0 NM 1 NM 1 NM 2 NM 1 NM
NCT02000947	PD-L1-positive NSCLC PD-L1-negative NSCLC PD-L1 0% NSCLC	18 37 24	NM 33 (13–59) NM 30 (16–47) NM 38 (19–59)

Notes: PD-L1 negative, <25% but <0% of tumor cells expressing PD-L1; PD-L1 positive, ≥25% of tumor cells expressing PD-L1.

Abbreviations: HCC, hepatocellular carcinoma; NM, not mentioned; NSCLC, non-small-cell lung cancer; NTNBC, non-triple-negative breast cancer; ORR, objective response rate; PD-L1, programmed cell death ligand-1; PR, partial response; RCC, renal cell carcinoma.